Tags

Type your tag names separated by a space and hit enter

WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception. 1982 Jan; 25(1):1-11.C

Abstract

A multicentre phase III clinical trial has been undertaken to compare norethisterone enantate (NET-EN) given by two different treatment regimens and depot-medroxyprogesterone acetate (DMPA). After 18 months of observation, preliminary findings are reported for 1,589 women who received DMPA 150mg every 90 days; 790 women who received NET-EN 200mg every 60 days; and 796 women who received NET-EN, 200mg every 60 days for 6 months, then 200mg every 84 days. The overall discontinuation rates per 100 women were similar for all three treatment groups over the 18 months observation (61.8 - 63.5 per 100 women). The discontinuation rates for bleeding problems and for personal reasons were also similar for all three treatment groups. However, terminations due to amenorrhoea were significantly higher among DMPA users (12.1 and 17.4 per 100 women at 12 and 18 months) as compared with both NET-EN groups (6.8 - 8.2 per 100 women at 12 months and 10.4 - 10.9 per 100 women at 18 months). The only significant difference in pregnancy rates observed between the three groups was a higher rate at 18 months among NET-EN (84 days) users (1.6 per 100 women), as compared with DMPA users (0.2 per 100 women). There was no overall significant difference between the two NET-EN groups, although between the 6 and 18 month's follow-up when the two NET-EN regimens diverged, the NET-EN (84 days) users' pregnancy rate rose significantly, whereas in the NET-EN (60 days) group the pregnancy rate did not change. There was a significantly higher weight gain in those subjects using NET-EN at 60-day intervals compared with those using it at 84-day intervals.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6460593

Citation

"WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force On Long-acting Agents for the Regulation of Fertility." Contraception, vol. 25, no. 1, 1982, pp. 1-11.
WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility. Contraception. 1982;25(1):1-11.
(1982). WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility. Contraception, 25(1), 1-11.
WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force On Long-acting Agents for the Regulation of Fertility. Contraception. 1982;25(1):1-11. PubMed PMID: 6460593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility. PY - 1982/1/1/pubmed PY - 1982/1/1/medline PY - 1982/1/1/entrez KW - Amenorrhea KW - Bleeding KW - Blood Pressure KW - Body Weight KW - Brazil KW - Chile KW - Clinical Research KW - Comparative Studies KW - Contraception KW - Contraception Termination--statistics KW - Contraceptive Agents, Female--administraction and dosage KW - Contraceptive Agents, Progestin--administraction and dosage KW - Contraceptive Agents--administraction and dosage KW - Contraceptive Methods KW - Demographic Factors KW - Diseases KW - Egypt KW - Family Planning KW - Fertility KW - Injectables KW - International Agencies KW - Italy KW - Luxembourg KW - Medroxyprogesterone Acetate--administraction and dosage KW - Menstruation Disorders KW - Mexico KW - Netherlands KW - Nigeria KW - Norethindrone Enanthate--administraction and dosage KW - Norethindrone--administraction and dosage KW - Organizations KW - Pakistan KW - Philippines KW - Population KW - Population Dynamics KW - Pregnancy, Unplanned KW - Reproductive Behavior KW - Research Methodology KW - Signs And Symptoms KW - Studies KW - Thailand KW - Un KW - Who KW - Yugoslavia KW - Zambia SP - 1 EP - 11 JF - Contraception JO - Contraception VL - 25 IS - 1 N2 - A multicentre phase III clinical trial has been undertaken to compare norethisterone enantate (NET-EN) given by two different treatment regimens and depot-medroxyprogesterone acetate (DMPA). After 18 months of observation, preliminary findings are reported for 1,589 women who received DMPA 150mg every 90 days; 790 women who received NET-EN 200mg every 60 days; and 796 women who received NET-EN, 200mg every 60 days for 6 months, then 200mg every 84 days. The overall discontinuation rates per 100 women were similar for all three treatment groups over the 18 months observation (61.8 - 63.5 per 100 women). The discontinuation rates for bleeding problems and for personal reasons were also similar for all three treatment groups. However, terminations due to amenorrhoea were significantly higher among DMPA users (12.1 and 17.4 per 100 women at 12 and 18 months) as compared with both NET-EN groups (6.8 - 8.2 per 100 women at 12 months and 10.4 - 10.9 per 100 women at 18 months). The only significant difference in pregnancy rates observed between the three groups was a higher rate at 18 months among NET-EN (84 days) users (1.6 per 100 women), as compared with DMPA users (0.2 per 100 women). There was no overall significant difference between the two NET-EN groups, although between the 6 and 18 month's follow-up when the two NET-EN regimens diverged, the NET-EN (84 days) users' pregnancy rate rose significantly, whereas in the NET-EN (60 days) group the pregnancy rate did not change. There was a significantly higher weight gain in those subjects using NET-EN at 60-day intervals compared with those using it at 84-day intervals. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/6460593/WHO_special_programme_of_research_development_and_research_training_in_human_reproduction__Task_force_on_long_acting_agents_for_the_regulation_of_fertility_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(82)90014-2 DB - PRIME DP - Unbound Medicine ER -